MDWD vs NAGE
MediWound Ltd. and Niagen Bioscience, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | MDWD | NAGE |
|---|---|---|
| Revenue | $17.0M | $129.4M |
| Net income | $-23.9M | $17.4M |
| Gross margin | 19.2% | 64.3% |
| Net margin | −140.8% | 13.4% |
| Return on equity | −63.9% | 28.3% |
| Diluted EPS | −$2.10 | $0.20 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $-21.6M | · |
| Equity | · | $76.5M |
| Net debt / equity | · | · |
| Current ratio | 2.33× | 4.86× |
| Revenue CAGR 5y | −4.9% | 16.9% |
| Profit CAGR 5y | · | · |
NAGE bills 7.6× the revenue of MDWD, and MDWD closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | MDWD | NAGE |
|---|---|---|
| FY2025 | $17.0M | $129.4M |
| FY2024 | $20.2M | $99.6M |
| FY2023 | $18.7M | $83.6M |
| FY2022 | $26.5M | $72.0M |
| FY2021 | $23.8M | $67.4M |
| FY2020 | $21.8M | $59.3M |
| FY2019 | $31.8M | $46.3M |
| FY2018 | $3.4M | $31.6M |
| FY2017 | $2.5M | $21.2M |
| FY2016 | $1.6M | $21.7M |
Bottom line
| Fiscal year | MDWD | NAGE |
|---|---|---|
| FY2025 | $-23.9M | $17.4M |
| FY2024 | $-30.2M | $8.6M |
| FY2023 | $-6.7M | $-4.9M |
| FY2022 | $-19.6M | $-16.5M |
| FY2021 | $-13.6M | $-27.1M |
| FY2020 | $-9.2M | $-19.9M |
| FY2019 | $5.0M | $-32.1M |
| FY2018 | $-1.1M | $-33.3M |
| FY2017 | $-22.1M | $-11.4M |
| FY2016 | $-18.9M | $-2.9M |
11 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$112,464,000 | NAGE |
| FY2024 | −$79,375,000 | NAGE |
| FY2023 | −$64,884,000 | NAGE |
| FY2022 | −$45,554,000 | NAGE |
| FY2021 | −$43,686,000 | NAGE |
| FY2020 | −$37,494,000 | NAGE |
| FY2019 | −$14,502,000 | NAGE |
| FY2018 | −$28,156,000 | NAGE |
| FY2017 | −$18,705,000 | NAGE |
| FY2016 | −$20,106,648 | NAGE |
| FY2015 | −$17,283,886 | NAGE |
NAGE has reported the higher revenue in every one of these 11 fiscal years. The gap has widened since the earliest year compared.
11 of 16 comparable fiscal years — a year missing data on either side is not counted.
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −154.2 pp | NAGE |
| FY2024 | −158.0 pp | NAGE |
| FY2023 | −30.0 pp | NAGE |
| FY2022 | −51.0 pp | NAGE |
| FY2021 | −16.8 pp | NAGE |
| FY2020 | −8.6 pp | NAGE |
| FY2019 | +85.0 pp | MDWD |
| FY2018 | +74.5 pp | MDWD |
| FY2017 | −833.7 pp | NAGE |
| FY2016 | −1198.6 pp | NAGE |
The higher net margin has changed hands between MDWD and NAGE over this period.
10 of 16 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MDWD's net margin has been more volatile than NAGE's over the 10 comparable fiscal years — 403.5 percentage points of standard deviation against 34.9.
10 of 16 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between MDWD and NAGE over these 10 fiscal years — MDWD led in 2 and NAGE in 8.
10 of 16 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MDWD's return on equity has been more volatile than NAGE's over the 9 comparable fiscal years — 78.8 percentage points of standard deviation against 52.2.
9 of 16 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between MDWD and NAGE over these 9 fiscal years — MDWD led in 3 and NAGE in 6.
9 of 16 comparable fiscal years — a year missing data on either side is not counted.